Author(s): Rebecca W. Van Dyke, M.D., 2012 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.

Slides:



Advertisements
Similar presentations
Author(s): John Levine, M.D., 2009 License:Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Advertisements

Author(s): Prachi Agarwal M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Don M. Blumenthal, 2010 License: Unless otherwise noted, this material is made available under the terms of the Attribution – Non-commercial.
Author(s): Paul Conway, License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Trisha Paul License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution-ShareAlike.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Caroline Richardson, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): John Doe, MD; Jane Doe, PhD, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): John Doe, MD; Jane Doe, PhD, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Templates for editing U-M OER Materials
Author(s): Paul Conway, License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): David Ginsburg, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.
Author: Jonathan Trobe, MD, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution 3.0.
Author(s): Seetha Monrad, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.
Project: Ghana Emergency Medicine Collaborative Document Title: Open Educational Resources Author(s): University of Michigan Department of Emergency Medicine.
Cholestatic liver diseases:
Module: Public Health Disaster Planning for Districts Organization: East Africa HEALTH Alliance, Author(s): Dr. Roy William Mayega (Makerere.
Author(s): Brenda Gunderson, Ph.D., 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author: Michael Jibson, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author(s): MELO 3D Project Team, 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation.
Author(s): MELO 3D Project Team, 2011 License: This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view a.
Project: Ghana Emergency Medicine Collaborative Document Title: Approach to Acute Chest Pain Author(s): Rockefeller Oteng (University of Michigan), MD.
Author(s): Brenda Gunderson, Ph.D., 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Joan Durrance, 2009 License: Unless otherwise noted, this material is made available under the terms of the Attribution - Non-commercial 3.0.
Project: Ghana Emergency Medicine Collaborative Document Title: Seizures Author(s): Ryan LaFollette, MD (University of Cincinnati), 2013 License: Unless.
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Arno Kumagai, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.
Author(s): Louis D’Alecy, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Attribution: Kim Eagle, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author: Michael Jibson, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author(s): Kate Saylor, 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author: John Williams, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Project: Ghana Emergency Medicine Collaborative Document Title: My Bougie and Me Author(s): Vijay Kairam (University of Utah), MD 2012 License: Unless.
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Brenda Gunderson, Ph.D., 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author: Michael Jibson, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Jonathan D. Trobe, M.D. License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author: Michael Jibson, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author: Michael Jibson, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Share.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Don M. Blumenthal, 2010 License: Unless otherwise noted, this material is made available under the terms of the Attribution – Non-commercial.
Author(s): MELO 3D Project Team, 2011 License: This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view a.
Author(s): Randall Sung, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Michael Hortsch, Ph.D., 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Gabriel Krieshok, Alex Pompe, 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons.
Author(s): MELO 3D Project Team, 2011 License: This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view a.
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Non-commercial–Share.
Author(s): Paul Conway, PhD, 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
Author(s): Paul Conway, PhD, 2010 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution.
1 Author(s): Andrew Rosenberg
Author: Michael Jibson, M.D., Ph.D., 2009
Author(s): John Doe, MD; Jane Doe, PhD, 2009
Author(s): Rajesh Mangrulkar, MD, 2009
Author(s): Paul Conway, PhD, 2010
Author: Robert Lyons, Ph.D., 2008
Author: Michael Jibson, M.D., Ph.D., 2009
Attribution: University of Michigan Medical School, Department of Internal Medicine License: Unless otherwise noted, this material is made available under.
1 Author(s): Rebecca W. Van Dyke, M.D., 2012
Author(s): Joan Durrance, 2009
1 Author(s): Rebecca W. Van Dyke, M.D., 2012
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available.
Attribution: Department of Neurology, 2009
Author: Michael Jibson, M.D., Ph.D., 2009
Presentation transcript:

Author(s): Rebecca W. Van Dyke, M.D., 2012 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution – Share Alike 3.0 License: We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

Attribution Key for more information see: Use + Share + Adapt Make Your Own Assessment Creative Commons – Attribution License Creative Commons – Attribution Share Alike License Creative Commons – Attribution Noncommercial License Creative Commons – Attribution Noncommercial Share Alike License GNU – Free Documentation License Creative Commons – Zero Waiver Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ Public Domain – Expired: Works that are no longer protected due to an expired copyright term. Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105) Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain. Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair. { Content the copyright holder, author, or law permits you to use, share and adapt. } { Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. } { Content Open.Michigan has used under a Fair Use determination. }

M2 GI Sequence Cholestatic Liver Diseases Rebecca W. Van Dyke, MD Winter 2012

Learning Objectives At the end of this lecture the student should be able to: 1. Define cholestatic and hepatocellular liver disease, provide examples of both and be able to interpret panels of liver tests. 2. Define the difference between intrahepatic and extrahepatic cholestasis and outline approaches to distinguishing them. 3. Define the pathophysiology of representative cholestatic diseases, including drug-induced cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and bile duct obstruction. 4. Outline an approach to the evaluation of the jaundiced patient. 5. Define acute and chronic hepatocellular liver disease and provide representative examples.

Industry Relationship Disclosures Industry Supported Research and Outside Relationships None

Common Types of Liver Disease Hepatocellular: Injury to hepatocytes (necrosis/apoptosis) Consequences: decreased synthetic/metabolic activity release of intracellular contents (AST/ALT) Cholestasis:Impaired bile formation (hepatocytes) Impaired bile flow (bile ducts/ductules) Consequences: build up in blood of substances normally excreted in bile (bilirubin, bile acids) synthesis/release of apical membrane proteins (AP)

Cholestasis = impaired bile flow Structures involved in secretion and passage of bile

Cholestatic Liver Disease Classification of cholestatic diseases: 1. A functional impairment in bile formation at the level of the hepatocyte. 2. A structural interference with normal bile secretion and flow at the level of small intrahepatic bile ducts. 3. A structural interference with normal bile flow at the level of large and extrahepatic bile ducts.

Cholestatic Liver Disease Biochemical cholestasis:increased serum bilirubin increased serum alkaline phosphatase Clinical cholestasis:jaundice dark urine/clay-colored feces pruritus Pathological cholestasis:bile plugs in dilated canaliculi increased bile pigment in hepatocytes bile lakes/bile infarcts biliary infection (acute cholangitis)

Tests for Evaluating Cholestasis Screening tests that suggest cholestasis –Color change in skin/sclerae/stool/urine –Laboratory biochemical tests (Alk Phos, Bilirubin) Diagnostic tests to establish proof of disease –Liver biopsy –Indirect visualization of dilated bile ducts and/or masses compressing bile ducts/stones (CT, U/S) –Direct visualization of lumen of bile ducts allowing identification of plumbing problems ERCP - endoscopic retrograde cholangiopancreatography MRCP - magnetic resonance cholangiopancreatography

Jaundice: Consequence of Cholestasis

Hypercarotenemia (hand on the right) – the only other potential disease in the differential diagnosis of yellow skin

Clinical Consequences of Severe Cholestasis: 1. Clay-colored stools 2. Bilirubin in urine

Cholestasis: Specific Examples 1. Intrahepatic cholestasis due to decreased bile formation: Sepsis Estrogens 2. Intrahepatic cholestasis due to diseases that alter intrahepatic bile ducts: Primary biliary cirrhosis Infiltration of liver with tumor/granulomas 3. Intrahepatic cholestasis due to any severe liver disease: Viral hepatitis 4. Extrahepatic bile duct obstruction: Tumor, gallstones, duct strictures Primary sclerosing cholangitis

Cholestasis: Specific Abnormalities in Bile Formation Transporters involved in uptake and biliary secretion of bilirubin and/or bile acids may be inhibited by various agents, leading to cholestasis and jaundice. Examples:Estrogens Endotoxin/tumor necrosis factor

Intrahepatic Cholestasis: Retained bile pigments/bilirubin in hepatocytes Retained bile

Intrahepatic Cholestasis Intrahepatic cholestasis due to diseases that compress and/or destroy intrahepatic bile ducts: Primary Biliary Cirrhosis Infiltration of liver with tumor/granulomas

Primary Biliary Cirrhosis Chronic, slowly evolving cholestatic disorder Primarily affects middle-aged women Primary lesion: –T cell mediated destruction of intrahepatic bile ducts –Slow progression to cirrhosis Relative sparing of hepatocytes with relative preservation of liver function

Primary Biliary Cirrhosis (PBC) Typical laboratory abnormalities: Alk Phos1050 IU/l(nl ) Bilirubin mg/dl (nl ) AST/ALT IU/l(nl 25-60) Albumin3.7 gm/dl(nl ) Prothrombin time11 seconds(nl 8-12) Cholesterol420 mg/dl(nl ) Antimitochondrial antibody:positive in 95% Liver copper: may be elevated due to chronic cholestasis

Early lesion of Primary Biliary Cirrhosis

Bile duct

Primary Biliary Cirrhosis (PBC) Clinical Findings: Jaundice Pruritus (related to retention of bile acids and other substances) Xanthomas/xanthalasmas (cholesterol deposits in skin)

Jaundice

Skin lesions on the back from scratching due to pruritus in Primary Biliary Cirrhosis

PBC: xanthalasmas

PBC: xanthomas

Infiltrative/Granulomatous Diseases Often present with cholestasis: elevated alkaline phosphatase with or without jaundice Increased alk phos due to compression of small intrahepatic bile ducts by expanding granulomas Examples:tuberculosis sarcoidosis

Hepatic Granulomas/Sarcoidosis

Hepatic Sarcoidosis: granulomas and giant cells

Extrahepatic Biliary Obstruction

Intrahepatic Perihilar Distal extrahepatic Duodenum Ampulla Of Vater Common bile duct Gallbladder Common hepatic duct Liver Extra- Hepatic Bile Ducts Obstruction of the bile ducts at any point outside the liver can cause cholestasis by blocking bile flow. Adapted from Gordon Flynn, Wikimedia CommonsWikimedia Commons

ERCP (normal) Endoscopic Retrograde CholangioPancreatography

Adapted from Gordon Flynn, Wikimedia CommonsWikimedia Commons Intrahepatic Perihilar Distal extrahepatic Duodenum Ampulla Of Vater Common bile duct Gallbladder Common hepatic duct Liver Does obstruction of the cystic duct or gallbladder cause jaundice? Adapted from Gordon Flynn, Wikimedia CommonsWikimedia Commons

Subsets of Extrahepatic Biliary Obstruction Intrinsic ObstructionExtrinsic Obstruction GallstonesTumor: Biliary Strictures pancreatic postsurgical cholangiocarcinoma Primary sclerosing cholangitis periampullary lymphoma Worms/parasites or metastatic tumor Blood clot/hemobiliaAcute/chronic pancreatitis (edema/fibrosis in head of pancreas) Congenital disease: biliary atresia choledochal cyst

Primary Sclerosing Cholangitis Slowly evolving disease with fibrosis, stricturing and inflammation around extrahepatic bile ducts. –May also affect intrahepatic ducts Primarily affects middle-aged men –Associated with ulcerative colitis. Complications include complete duct obstruction, jaundice, biliary infection (cholangitis), pruritus. Relative preservation of hepatocytes.

Primary Sclerosing Cholangitis Typical laboratory abnormalities: Alk Phos875 IU/l(nl ) Bilirubin mg/dl(nl ) AST/ALT IU/l(nl 25-60) Albumin3.5 gm/dl(nl ) Prothrombin time11 seconds(nl 8-12)

Primary Sclerosing Cholangitis Typical Clinical Findings: Bile duct obstruction: best seen on direct imaging Jaundice and dilated bile ducts if complete obstruction of major duct occurs. Bile plugs/bile lakes/bile infarcts on liver biopsy Biliary infection (cholangitis) - acute bacterial infection of stagnant bile. Cirrhosis

Sclerosing Cholangitis: “onion-skinning fibrosis” around bile ducts very thickened bile duct wall decreases luminal diameter

Biliary obstruction When bile ducts are obstructed, what happens to the bile? What happens to the bile duct upstream of the obstruction?

Evidence of Bile Duct Obstruction: Dilated ducts upstream of the obstruction Bile-filled dilated bile ducts are large dark gray tubular structures that run parallel to the portal veins (white arrows). Portal veins are white due to IV contrast. liver parenchyma is light gray due to IV contrast.

Dilated bile ducts and gallbladder Gallbladder Dilated bile ducts Mass in head of the pancreas

Bile Duct Obstruction: Bile Plugs in Bile Ducts Portal vein HA

More canalicular cholestasis

Acute Cholangitis: PMNs in Bile Duct HA

Other Causes of Extra-hepatic Biliary Obstruction

High grade cholangiocarcinoma at the hilum

High grade bilateral obstruction from metastatic rectal carcinoma

Biliary stricture due to cholangiocarcinoma Alk phos = 669 IU Bili = 17.5 mg/dl AST = 68 IU ALT = 38 IU

More permanent metal mesh stent placed A plastic stent bridges the stenosis

Bile duct obstruction from chronic pancreatitis

Biliary Obstruction: Multiple stones in biliary tree

Large ducts near hilum massively dilated Small peripheral ducts also enlarged and visible Bile Duct Dilation due to Obstruction

An unusual cause of biliary obstruction Radio-opaque dye injected through T-tube fills common bile duct and intrahepatic bile ducts. Dark linear structures are ascariasis located in biliary system (black arrows).

Ascaris emerging from common bile duct as seen endoscopically

Consequences of Cholestasis Secondary liver damage –Bile acid-induced hepatocyte injury –Secondary biliary cirrhosis Failure of substances secreted in bile to reach intestine –Bile acid deficiency in gut –Fat malabsorption/fat-soluble vitamin malabsorption

SUMMARY: EVALUATION OF CHOLESTASIS AND/OR JAUNDICE 1. Suspect cholestasis based on history, physical exam, lab tests. 2. Look for clues to mechanical obstruction of ducts and/or mass lesions (radiologic studies). 3. Visualize, diagnose and treat mechanical obstruction. 4. Consider intrahepatic cholestasis, obtain liver biopsy. See algorithms in syllabus and in textbook

Additional Source Information for more information see: Slide 32 & 34: Adapted from Gordon Flynn, Wikimedia Commons, CC:BY- SA,